Cathelicidin, hCAP-18 Fragment
Evidence Grade B — Strong clinical evidence. 2447 published studies, 1780 human. 20 registered clinical trials.
LL-37 is the only antimicrobial peptide of its type (cathelicidin) produced by the human body, naturally released by immune cells and skin cells as part of the innate immune defence. Synthetic versions have been tested in early clinical trials for melanoma skin cancer, diabetic foot ulcers, and leg ulcers. It has no marketing authorisation.
2,447 published studies: 1780 human, 166 animal, 532 in-vitro, 243 reviews
LL-37 has no marketing authorisation. Early-phase clinical trials have been conducted: a Phase I/II study of intratumoral injection in melanoma reported local tumour regression; Phase II trials in diabetic foot ulcers and venous leg ulcers have assessed wound healing applications.
LL-37 is of significant scientific interest as the sole human cathelicidin and has an extensive preclinical literature on antimicrobial and immunomodulatory properties. Clinical development remains at an early stage, and no Phase III trials have been completed.
Research suggests LL-37 has direct antimicrobial activity by disrupting bacterial cell membranes, combined with broader immune-modulating effects including immune cell recruitment, inflammation regulation, and promotion of wound healing. These dual properties — direct pathogen killing plus immune system coordination — are characteristic of antimicrobial peptides as a class. Clinical translation is being investigated but is not yet established.
Research suggests LL-37 has dual properties — direct bacterial killing combined with immune system coordination — that make it scientifically interesting as a potential therapeutic. A Phase I/II melanoma trial showed local tumour regression with direct injection, and Phase II wound healing trials have been conducted. Clinical development remains at an early stage with no Phase III trials completed. Practical challenges include a very short half-life in the blood (under 30 minutes), toxicity at higher concentrations, and high manufacturing cost for a 37-amino-acid peptide. The compound is also elevated in rosacea, illustrating its dual pro-and anti-inflammatory nature. Research into shorter active fragments and nanoparticle delivery systems aims to address these limitations.
Evaluation of 25(OH)D3 and LL-37 Levels in Periimplant Sulcus Fluid
Cathelicidin LL-37 Relation to Potentially Malignant Lesions
Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children
Chlorhexidine and Essential Oil Mouthwashes on Human Beta-Defensin 2 (hbD2) and Kathelicidin (LL-37) Saliva Levels
The Role of Anti-inflammatory Cytokines and Antimicrobial Peptide LL-37 Biomarkers in the Treatment of Periodontal Disease.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Corticotropin is marketed as H.P. Acthar Gel (currently ANI Pharmaceuticals). It carries approximately 19 FDA-labelled indications including infantile spasms (its strongest evidence base), nephrotic syndrome, multiple sclerosis relapses, and rheumatic disorders. Acthar Gel has been at the centre of major pricing and legal controversies. The price rose from approximately $40 per vial in 2001 to over $40,000, driven by successive acquisitions and orphan-like positioning despite broad labelling. The former manufacturer Mallinckrodt agreed to a $260 million settlement over antitrust concerns. Clinically, the strongest evidence supports its use in infantile spasms, where it is considered a first-line treatment. For most other indications, debate continues over whether it offers meaningful advantages over far less expensive oral corticosteroids.
Enfuvirtide is marketed as Fuzeon (approved March 2003). It requires twice-daily subcutaneous injections, and injection-site reactions occur in nearly all patients (98%). In clinical trials (TORO-1 and TORO-2), enfuvirtide combined with an optimised background regimen achieved significantly greater viral suppression than background regimen alone in treatment-experienced patients. Enfuvirtide represented a major advance when HIV drug resistance was a more pressing clinical challenge, but its use has declined substantially with the arrival of more convenient oral antiretrovirals. The twice-daily injection burden, injection-site reactions, high cost, and complex manufacturing (it is one of the largest synthetic peptides manufactured at scale) have limited its role to a last-resort option for patients with highly resistant HIV.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
